Ritujith Jayakrishnan
Overview
Explore the profile of Ritujith Jayakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, et al.
Eur J Cancer
. 2025 Feb;
219:115302.
PMID: 39987799
Introduction: The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patients, often...
2.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
3.
Jaber Chehayeb R, Singh J, Matute-Martinez C, Chen N, Guajardo A, Lin D, et al.
Cardiooncology
. 2024 Nov;
10(1):84.
PMID: 39587635
Background: Clonal hematopoiesis of indeterminate potential (CHIP) has been shown to increase all-cause mortality and risk of cardiomyopathy in patients with solid malignancies. CHIP has also been shown to increase...
4.
Nassar A, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung J, et al.
J Thorac Oncol
. 2024 Sep;
20(1):109-118.
PMID: 39260522
Introduction: Patients with advanced ALK-positive NSCLC typically have poor response to immunotherapy; the benefit of consolidation durvalumab in patients with unresectable stage III ALK-positive NSCLC remains unclear. Herein, we compare...
5.
Leveille E, Jaber Cheheyeb R, Matute-Martinez C, Chen N, Jayakrishnan R, Christofides A, et al.
JACC CardioOncol
. 2024 Sep;
6(4):605-607.
PMID: 39239339
No abstract available.
6.
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A
Oncologist
. 2024 Jun;
29(10):833-841.
PMID: 38907669
The genome of a cell is continuously battered by a plethora of exogenous and endogenous processes that can lead to damaged DNA. Repair mechanisms correct this damage most of the...
7.
Carey G, Holleck J, Alshaeba S, Jayakrishnan R, Gordon K, Grimshaw A, et al.
J Antimicrob Chemother
. 2023 Mar;
78(5):1150-1159.
PMID: 36964648
Objectives: We performed a systematic review and meta-analysis to estimate the effect of early active empirical antibiotics for MRSA on mortality, both in patients admitted with MRSA infections and in...
8.
Saloner B, Landis R, Jayakrishnan R, Stein B, Barry C
Subst Abus
. 2022 Jan;
43(1):682-690.
PMID: 35099362
Travel distance to medication treatment for opioid use disorder (OUD) is a challenge for many patients, but little is known about how distance is associated with medication treatment utilization. This...
9.
Ugurluer G, Chang K, Gamez M, Arnett A, Jayakrishnan R, Miller R, et al.
Anticancer Res
. 2016 Apr;
36(5):2331-8.
PMID: 27127140
Background/aim: Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with...
10.
Jayakrishnan R, Chang K, Ugurluer G, Miller R, Sio T
Oncol Rev
. 2016 Jan;
9(1):290.
PMID: 26779314
Radiotherapy (RT), an integral part of the oncologic treatment for patients with head and neck cancer, can cause adverse side effects such as oral mucositis (OM). Pain from OM can...